Conner Childers, JD, Joins Beckman Coulter as Vice President, Head of Global Compliance

Former Healthcare Compliance Policy Director at Amgen

Life Science Partner partnered with Beckman Coulter to recruit Conner Childers, JD, to serve as Vice President, Head of Global Compliance for Beckman Coulter.  He will report to Curt Brueske, JD, General Counsel.

In his most recent role at Amgen, Childers had direct responsibility for building the compliance program so that the company was prepared to respond to the company’s first Corporate Integrity Agreement.  Working across Amgen’s U.S. operations, Childers recruited and led a team that made compliance part of the corporate commercial objectives.

With his Amgen experience in building new compliance programs in partnership with business units, Childers has the right balance of leadership and influence to build an effective Beckman Coulter compliance organization,” states Tom Callaway, MD, Founder and President of Life Science Partner. “His legal and organizational background including a career as a Naval Officer have given him the skills and ability to build and lead world class teams.”

Childers earned his Bachelor of Arts Degree in Government from Claremont McKenna College and his Juris Doctorate from the University of Arizona, College of Law.


Jeremy Miller, MD, Joins EndoChoice as Pathology Director

Former Director of Urologic Pathology/GI Pathology at Ameripath

Life Science Partner has recruited Jeremy Miller, MD, to lead the Pathology Lab at EndoChoice, a College of American Pathology (CAP) accredited lab focused on providing the highest level of quality and service to the GI community.

Miller joins EndoChoice after serving as Director of Urologic Pathology and GI Pathology at Ameripath, in addition to formerly serving as Chief Medical Officer for Platinum Pathology, a national GI and GU lab owned by Miller based out of Virginia.

“Miller has excellent training as a pathologist with broad surgical pathology training, he has worked directly under internationally-renowned Dr. Fenoglio-Preiser, one of the top GI leaders in the field,” states Tom Callaway, MD, President and Founder of Life Science Partner.  “He is an entrepreneurial leader in the field of high volume pathology with a can-do attitude that will fit with the corporate culture of EndoChoice.”

Miller earned a Bachelor of Science Degree in Engineering from Duke University and his MD from the Medical College of Georgia.  Miller completed his Fellowship in Genitourinary Surgical Pathology from the The Johns Hopkins Hospital.

Joe Jimenez Joins TissueTech as Vice President, Quality Assurance and Regulatory Affairs

Former Vice President, PGT Quality Teva Pharmaceuticals

Joe Jimenez, Vice President, formerly PGT Quality for Teva Pharmaceuticals has recently become Vice President, Quality Assurance and Regulatory Affairs for TissueTech, a Miami-based company producing regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets.    Life Science Partner partnered with CEO Amy Tseng and founder Shefferd Tseng, MD, PhD, to recruit Jimenez to prepare the company for the changing regulatory landscape of regenerative medicine products.

At Teva, Jimenez was responsible for leading the global quality team for the PGT joint venture between Proctor & Gamble and Teva where he oversaw an international team based in Switzerland.  “Jimenez has global view of quality,” states Tom Callaway, MD, Founder and President of Life Science Partner.  “He has a broad hands-on approach to developing analytical methods and quality systems combined with a can-do energy that will mesh well with the culture at TissueTech.”

Jimenez earned a Bachelor of Arts degree in Chemistry from Queens College in New York.

Susan Blank Joins BioConfirm Laboratories as Chief Medical Officer

Founder and Chief Medical Officer of Atlanta Healing Center and President of the Georgia Society of Addiction Medicine
Life Science Partner is pleased to announce the recruitment of Susan Blank, MD, Founder and Chief Medical Officer for the Atlanta Healing Center to become the Chief Medical Officer for BioConfirm Laboratories-a new company based in Atlanta committed to providing personalized physician-led solutions and services for patients and clinicians surrounding addiction and substance abuse.

With her entire career focused on the treatment of addiction and behavioral health with a true passion for healing through comprehensive programs, Life Science Partner identified Blank as a key expert for establishing the therapy platform at BioConfirm.

As an active expert and advocate for addiction recovery, Blank can be heard nationwide every Tuesday on her weekly radio show “Detailing Addiction” on America’s Web Radio. “Her passion, enthusiasm, and in depth knowledge of comprehensive addiction therapy will be a major asset to BioConfirm’s growth,” states Tom Callaway, President and Founder of Life Science Partner.

Blank earned her Bachelor of Arts degree in Psychology from Augusta College and she completed her MD from the Medical College of Georgia.

Robert Rajalingam Joins Smiths Medical as VP, Global Product Management, Vascular Access

Former Site Leader and Vice President for Global Marketing at Medtronic/Covidien Vascular Therapies

As a medical device leader and strategic marketing executive, Robert Rajalingam has been selected to lead Smith Medical’s $300 M Vascular Access business.  Life Science Partner collaborated closely with Vice President, Carl Stamp to recruit Rajalingam from Medtronic.

Vascular medicine has been his passion and interest, having worked both in the venous therapy area (spearheading the re-branding with Rethink Varicose Veins campaign including an Olympic spokesperson at Covidien) and in arterial disease at Medtronic Vascular in business development, including a partnership with Abbott Vascular.

“Robert is passionate and articulate about medical devices and their ability to improve patient lives. Experienced in managing a maturing product portfolio while simultaneously spearheading product innovation, he has the know-how, tenacity, and marketing instincts to build highly effective teams at Smiths Medical,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Rajalingam earned his Bachelor of Science in Engineering degree from Duke University and his MBA from Stanford Graduate School of Business.



Susan Alpert, MD, PhD joins Canary Medical as Regulatory Affairs Leader

Former Senior Vice President, Chief Regulatory Officer at Medtronic

As one of the foremost leaders in the complex regulatory arena of medical devices, combination products, and healthcare information, Susan Alpert, MD, PhD, has been recruited by Life Science Partner to serve as the top regulatory advisor for Canary Medical.

Canary Medical has established an innovative portfolio of intellectual property surrounding its CHIRP (Canary Medical Implantable Recording Processor) technology that is transforming the medical field as it allows medical device manufacturers to integrate a 1cc implanted device for wireless data transmission.

“As a seasoned expert within the inner workings of the FDA on healthcare data and appropriate management of patient information, the regulatory role at Canary will be a natural fit for Alpert following her retirement from Medtronic,” states Tom Callaway, MD, President of Life Science Partner.  “Alpert will be an invaluable source for Canary’s rapidly growing company and current leadership team- Bill Hunter, CEO and Jeff Gross, CTO.

Susan completed her bachelor’s degree at Barnard College, Columbia University in New York City and holds a master’s degree and Ph.D. in Biomedical Sciences from New York University. She received her medical degree from the University of Miami (Florida) and completed her clinical training at Montefiore Medical Center in the Bronx, New York and at Children’s National Medical Center in Washington, D.C.

Reggie Groves Discusses REVA’s New Bioresorbable Stent

Congratulations to REVA Medical CEO and former Life Science Partner placement Reggie Groves on her feature in this week’s San Diego Business Journal!

View the feature here.

Bill Bold Joins Vestagen Technical Textiles as Chief Executive Officer

Former President and Chief Executive Officer of Vascular Pathways

Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.

Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.

“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.

Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.

Bold earned a Bachelor of Science Degree in Marketing from West Chester University.


Michel Hermans, MD Joins TissueTech as Chief Medical Officer

Former Medical Director, Global Medical Marketing, ConvaTec

Life Science Partner recruited Michel Hermans, MD, a surgically trained medical affairs executive to become Chief Medical Officer for TissueTech.

Hermans joins TissueTech after serving as a biopharma consultant for his own firm and Medical Director, Global Medical Marketing for ConvaTech.   Previously, Hermans served served as Medical Director for Ortec where he successfully led the new clinical trials for the commercialization of OrCel globally.

TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, orthopedic reconstructive surgeries and wound care markets.

TissueTech offers its portfolio products through its commercial entities: BioTissue, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, and Amniox Medical, a leading technology provider to the orthopedic and wound care markets.

“Hermans has the direct clinical trials management experience that leads to the approval of biologics in the BLA regulatory pathway – and brings that background to TissueTech’s clinical and regulatory strategy,” states Tom Callaway, MD, Founder and President of Life Science Partner.  “In addition, as a specialist in treating burn patients, he brings real-life clinical experience to the company.”

Hermans earned his Medical Degree from the University of Groningen in the Netherlands and completed his training in general surgery, burn and trauma care from the Rode Kruis Ziekenhuis and Burn Center in Beverwijk, Netherlands.


Abiomed to Appoint Seth Bilazarian, M.D., New Vice President of Interventional Cardiology Programs

DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Seth Bilazarian, M.D. will be appointed as Vice President of Interventional Cardiology Programs, effective October 8, 2015.

“We are excited to welcome Dr. Seth Bilazarian to Abiomed, where he will add a specialized interventional cardiology perspective to the executive team that will further strengthen our mission to recover hearts and save lives. Seth has over 20 years of experience practicing interventional cardiology in the cath lab and has developed an expertise in hemodynamic support. His insight and knowledge will richly enhance our ongoing training and education initiatives for the new standard of care,” said Michael R. Minogue, President, Chairman and Chief Executive Officer, Abiomed.

“I am thrilled to become part of the Abiomed team. As a user, I am very familiar with the benefits of Impella and know it is transforming the standard of care in treating complex patients. I am eager to collaborate with expert and experienced physician users in interventional cardiology and heart failure to develop best practices for use of the Impella platform in Protected PCI,” said Seth Bilazarian, M.D.  “Educating physicians more broadly on the safe, effective and appropriate use of this technology will also be a focus. I am equally enthusiastic about the opportunity to begin working with industry colleagues to bring new devices within the Impella platform to market and continue the collaborative mission of recovering hearts.”

Dr. Bilazarian is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center and Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. Most recently, he was the Director of Clinical Cardiology Research Program and Clinical Cardiologist at Pentucket Medical Associates, LLC. He also serves on the faculty as an instructor in medicine at Harvard Medical School, where he has taught since 1995 and is the founder and director of the largest community based cardiac research program in the Partner’s network.

Dr. Bilazarian is board certified in cardiovascular medicine, nuclear cardiology, vascular ultrasound, interventional cardiology, and vascular and endovascular medicine. Dr. Bilazarian is an active participant in outpatient clinical trials in congestive heart failure, hypertension, heart disease prevention, diabetes, anemia, atrial fibrillation, anti-inflammatory strategies for vascular prevention and anticoagulation and anti-platelet therapies. In 2008, he was appointed as physician advisor to the cardiac device panel of the Food & Drug Administration.

In addition to his clinical practice, Dr. Bilazarian is an active blogger in the physician community. His blog, “Practitioner’s Corner with Dr. Seth Bilazarian” was established in 2009 and is hosted on and MedScape ( He has written over 100 blog posts that cover various topics across the wide spectrum of interventional cardiology.

Dr. Bilazarian received a Bachelor of Science in Engineering in Chemical Engineering from Tufts University and MD from University of Massachusetts Medical School. He completed his internship and residency at The Johns Hopkins Hospital in Baltimore, and cardiology and interventional cardiology fellowship at Boston University Hospital and Boston City Hospital.

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information please visit:

This release contains forward-looking statements, including statements regarding our expectation of a smooth transition to a new Vice President and Chief Financial Officer, the Company’s expectations of continued commercial growth, and future opportunities, including the opportunity to become the standard of care. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


For more information, please contact:

Aimee Genzler
Director, Corporate Communications

Ingrid Goldberg
Director, Investor Relations